{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_17904", "batch_size": 260, "batch_pos": 78, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment states facts neutrally without high-potency language.", "method": "llm_batch", "batch_id": "batch_2_16476", "batch_size": 260, "batch_pos": 68, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_13172", "batch_size": 260, "batch_pos": 51, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "Segment contains no question.", "method": "llm_batch", "batch_id": "batch_4_12724", "batch_size": 260, "batch_pos": 46, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports Moderna's mRNA research history, which is factual information without calming cues.", "method": "llm_batch", "batch_id": "batch_5_15664", "batch_size": 260, "batch_pos": 43, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser with scale contrast.", "method": "llm_batch", "batch_id": "batch_6_16336", "batch_size": 260, "batch_pos": 25, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The negation 'has no contracts yet' is not a bare negation about risk/cases/spread.", "method": "llm_batch", "batch_id": "batch_7_7224", "batch_size": 260, "batch_pos": 22, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes research history ('mRNA vaccine research actually began with pandemic flu') as past development capability without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_1736", "batch_size": 260, "batch_pos": 226, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
